Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Nucl Med Biol. 2009 Aug;36(6):659–669. doi: 10.1016/j.nucmedbio.2009.04.003

Table 1.

Treatment response observed in athymic rats with carcinomatous meningitis treated with single intrathecal injection of 211At-trastuzumab or controls

Experiment 1: 1.25 × 107 cell inoculum
Treatment Dose Rats/group Median
survival
(days)		 Survival
advantage
(%)a 		Significance
vs. saline
Saline -- 9 21 -- --
Cold trastuzumab 14 µg 10 21 0 Not
significant
211At-trastuzumab 33 µCi/14 µg 8 45 214 P <0.005
211At-trastuzumab 66 µCi/14 µg 9 48 229 P <0.005
Experiment 2: 5.0 × 106 cell inoculum
Treatment Dose Rats/group Median
survival
(days)		 Survival
advantage (%)		 Significance
vs. saline
Saline -- 10 23 -- --
211At-trastuzumab 46 µCi/19 µg 10 68 296 P <0.001
211At-trastuzumab 92 µCi/19 µg 11 92 400 P <0.001
Experiment 3: 5.0 × 106 cell inoculum
Treatment Dose Rats/group Median
survival
(days)		 Survival
advantage (%)		 Significance
vs. saline
Saline -- 11 20 -- --
211At-trastuzumab 28 µCi/20 µg 10 36 180 P <0.005
211At-TPS3.2 30 µCi/16 µg 9 29 145 P <0.005
a

Percent survival advantage is calculated as the median survival of treated mice divided by the median survival of mice receiving saline × 100